Logo image of PCLA

PICOCELA INC (PCLA) Stock Fundamental Analysis

NASDAQ:PCLA - Nasdaq - US71989C1099 - ADR - Currency: USD

0.471  -0.03 (-5.8%)

Premarket: 0.4713 +0 (+0.06%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to PCLA. PCLA was compared to 48 industry peers in the Communications Equipment industry. PCLA may be in some trouble as it scores bad on both profitability and health. PCLA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year PCLA has reported negative net income.
In the past year PCLA has reported a negative cash flow from operations.
PCLA Yearly Net Income VS EBIT VS OCF VS FCFPCLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -200M -400M -600M

1.2 Ratios

The Return On Assets of PCLA (-38.87%) is worse than 79.17% of its industry peers.
The Return On Equity of PCLA (-135.27%) is worse than 79.17% of its industry peers.
Industry RankSector Rank
ROA -38.87%
ROE -135.27%
ROIC N/A
ROA(3y)-31.59%
ROA(5y)N/A
ROE(3y)-75.82%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PCLA Yearly ROA, ROE, ROICPCLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

With a decent Gross Margin value of 53.95%, PCLA is doing good in the industry, outperforming 70.83% of the companies in the same industry.
PCLA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 53.95%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PCLA Yearly Profit, Operating, Gross MarginsPCLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 50 -50 -100

3

2. Health

2.1 Basic Checks

PCLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PCLA has a worse debt to assets ratio.
PCLA Yearly Total Debt VS Total AssetsPCLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

PCLA has an Altman-Z score of -0.98. This is a bad value and indicates that PCLA is not financially healthy and even has some risk of bankruptcy.
PCLA has a worse Altman-Z score (-0.98) than 70.83% of its industry peers.
PCLA has a Debt/Equity ratio of 0.93. This is a neutral value indicating PCLA is somewhat dependend on debt financing.
The Debt to Equity ratio of PCLA (0.93) is worse than 75.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.93
Debt/FCF N/A
Altman-Z -0.98
ROIC/WACCN/A
WACC1.69%
PCLA Yearly LT Debt VS Equity VS FCFPCLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 500M -500M

2.3 Liquidity

PCLA has a Current Ratio of 2.18. This indicates that PCLA is financially healthy and has no problem in meeting its short term obligations.
PCLA has a better Current ratio (2.18) than 68.75% of its industry peers.
A Quick Ratio of 1.70 indicates that PCLA should not have too much problems paying its short term obligations.
PCLA has a better Quick ratio (1.70) than 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 2.18
Quick Ratio 1.7
PCLA Yearly Current Assets VS Current LiabilitesPCLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 200M 400M 600M 800M 1B

1

3. Growth

3.1 Past

The earnings per share for PCLA have decreased strongly by -73.21% in the last year.
The Revenue has grown by 40.19% in the past year. This is a very strong growth!
EPS 1Y (TTM)-73.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-73.21%
Revenue 1Y (TTM)40.19%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%40.19%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PCLA Yearly Revenue VS EstimatesPCLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 200M 400M 600M

0

4. Valuation

4.1 Price/Earnings Ratio

PCLA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PCLA Price Earnings VS Forward Price EarningsPCLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PCLA Per share dataPCLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 0.1 0.15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for PCLA!.
Industry RankSector Rank
Dividend Yield N/A

PICOCELA INC

NASDAQ:PCLA (8/19/2025, 8:11:44 PM)

Premarket: 0.4713 +0 (+0.06%)

0.471

-0.03 (-5.8%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryCommunications Equipment
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.76%
Inst Owner Change10.83%
Ins Owners12.38%
Ins Owner ChangeN/A
Market Cap15.69M
AnalystsN/A
Price TargetN/A
Short Float %0.85%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.96
P/FCF N/A
P/OCF N/A
P/B 6.54
P/tB 7.22
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0.16
BVpS0.07
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.87%
ROE -135.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 53.95%
FCFM N/A
ROA(3y)-31.59%
ROA(5y)N/A
ROE(3y)-75.82%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0.93
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 213.01%
Cap/Sales 5.61%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.18
Quick Ratio 1.7
Altman-Z -0.98
F-Score4
WACC1.69%
ROIC/WACCN/A
Cap/Depr(3y)189.6%
Cap/Depr(5y)N/A
Cap/Sales(3y)3.85%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-73.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-73.21%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)40.19%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%40.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y28.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y62.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y67.18%
OCF growth 3YN/A
OCF growth 5YN/A